Open AccessBioequivalence of perampanel fine granules and tablets in healthy Japanese subjects
Author(s) -
Sari Shiba,
Hisakuni Sekino,
Kaeko Ishiba,
Shigeru Yasuda,
Syuhei Inoue,
Ken Kotaka,
Larisa Reyderman,
Naoki Uchida
Publication year - 2020
Publication title -
international journal of clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.363
H-Index - 67
ISSN - 0946-1965
DOI - 10.5414/cp203781
Subject(s) - bioequivalence , perampanel , pharmacology , medicine , bioavailability , pharmacokinetics , adverse effect
Perampanel is an approved anti-seizure drug. A new formulation of perampanel fine granules (FG; 1% perampanel) has been developed for patients who are unable to take tablets. Bioequivalence between the 4-mg FG and tablet perampanel formulations, as well as their safety and tolerability, were assessed.